- Home
- AACT vs GERN Comparison
AACT vs GERN Comparison
Compare AACT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACT
- GERN
- Stock Information
- Founded
- AACT 2021
- GERN 1990
- Country
- AACT United States
- GERN United States
- Employees
- AACT N/A
- GERN N/A
- Industry
- AACT
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- AACT
- GERN Health Care
- Exchange
- AACT Nasdaq
- GERN Nasdaq
- Market Cap
- AACT 705.2M
- GERN 823.0M
- IPO Year
- AACT 2023
- GERN 1996
- Fundamental
- Price
- AACT $11.40
- GERN $1.32
- Analyst Decision
- AACT
- GERN Buy
- Analyst Count
- AACT 0
- GERN 8
- Target Price
- AACT N/A
- GERN $3.71
- AVG Volume (30 Days)
- AACT 538.2K
- GERN 5.5M
- Earning Date
- AACT 01-01-0001
- GERN 11-06-2025
- Dividend Yield
- AACT N/A
- GERN N/A
- EPS Growth
- AACT N/A
- GERN N/A
- EPS
- AACT 0.26
- GERN N/A
- Revenue
- AACT N/A
- GERN $164,447,000.00
- Revenue This Year
- AACT N/A
- GERN $175.15
- Revenue Next Year
- AACT N/A
- GERN $56.61
- P/E Ratio
- AACT $43.55
- GERN N/A
- Revenue Growth
- AACT N/A
- GERN 11877.20
- 52 Week Low
- AACT $10.80
- GERN $1.09
- 52 Week High
- AACT $11.62
- GERN $4.83
- Technical
- Relative Strength Index (RSI)
- AACT 48.97
- GERN 47.49
- Support Level
- AACT $11.38
- GERN $1.23
- Resistance Level
- AACT $11.44
- GERN $1.33
- Average True Range (ATR)
- AACT 0.02
- GERN 0.07
- MACD
- AACT -0.00
- GERN -0.01
- Stochastic Oscillator
- AACT 25.00
- GERN 31.03
About AACT Ares Acquisition Corporation II
Ares Acquisition Corp II is a blank check company.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.